According to CFDA data, the medical device market in 2018 continued the high growth trend in recent years.
From 2011 to 2018, the average annual compound growth rate of China’s medical technology and medical device, industry is as high as 20.7%, far higher than the global average annual compound growth rate of about 3%.
In 2018, the scale of China’s medical device market is about 370 billion yuan.
It is estimated that the market size will reach 600 billion by 2019.
Among them, imaging equipment, in vitro diagnosis and high-value consumables occupy the top three parts of the medical device market, accounting for 19%, 16% and 13% of the total market size respectively.
Policy, market and new technology are still the three main factors affecting the development of China’s medical device industry.
Six innovative medical device investment directions include: imaging equipment sub industry, in vitro diagnosis sub industry, cardio cerebrovascular sub industry, tumor related equipment sub industry, surgery and orthopedic equipment sub industry, and medical artificial intelligence sub industry.
1.Imaging equipment sub industry
Data of the Research Report on investment in China’s big health industry from 2018 to 2020 Medical imaging industry is mainly divided into upstream medical imaging equipment and consumables and downstream imaging diagnosis services.
Medical imaging is also one of the top segmentation industries in the global medical device scale.
In 2012, the global medical device market sales reached 349 billion US dollars, including 36.1 billion US dollars of imaging diagnostic products, ranking the third in the global medical device market with 10.3% market share.
China is the fourth largest medical imaging market in the world, accounting for 12% of the global share.
2. Investment direction of innovative imaging equipment sub industry
For general-purpose large-scale equipment, such as CT, MRI, PET-CT and other fields, there are few excellent early projects and high valuation.
We are more optimistic about the imaging equipment in the subdivision field, especially those with unique hardware and artificial intelligence algorithm, such as breast cancer ultrasound, dental cone beam CT and so on.
In addition, we are also optimistic about mastering the core technology and other image core components upstream enterprises.
3. In vitro diagnosis sub industry
Data of the Research Report on investment in China’s big health industry from 2018 to 2020 In vitro diagnostic reagents include blood, biochemistry, immunity, molecular biology, bacteria, POCT and so on.
China’s IVD reagent industry has a certain market scale and foundation, and is stepping into a growth period from the industry introduction stage, with a good market prospect.
According to statistics, in 2014-2015, 1 / 3 of the medical device related investment and acquisition cases involving 50 million US dollars were involved in in in vitro diagnosis.
In 2016, the market scale of IVD in China was about 51 billion yuan, which is expected to maintain a growth rate of 15% – 20% in the next three to five years, and will exceed 85 billion yuan in 2020.
Compared with foreign mature markets, the scale of IVD industry in China is still relatively small.
China’s population accounts for more than one-fifth of the world’s population, but its share in the field of in vitro diagnostic reagents only accounts for 4% of the world’s total. The per capita annual consumption of IVD products in China is US $1.5, while that of developed countries is US $25-30.
The development of in vitro diagnostic reagents industry in China is characterized by large market, but greater market potential.
Therefore, IVD reagent is a hot spot in the investment and financing of medical device industry.
Investment direction of sub industry of innovation in vitro diagnosis:
A drop of blood, a breath, a mouthful of foam, can achieve a comprehensive detection of the disease, is the future development trend. How to find an effective and reliable test method at the right entrance is the difficulty in this field.
Molecular diagnosis and immediate testing (POCT) is still the main direction of innovation.
In molecular diagnosis, big data and artificial intelligence will change the overall pattern of molecular diagnosis.
For example, the sequencing services of gene sequencing are facing a new round of shuffling, and companies with their own databases, core algorithms and clinical interpretation capabilities will have the opportunity to break through.
The localization of upstream related reagents for gene sequencing will also be an important opportunity.
At present, the market education of concomitant diagnosis of cancer has been basically mature, which is one of the directions worthy of investment.